Oppenheimer has recently reiterated Keros Therapeutics Inc (KROS) stock to Outperform rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 16, 2024, Guggenheim had ...

Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from ...

Keros Therapeutics (KROS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

Oppenheimer analyst Andreas Argyrides reiterated a Buy rating on Keros Therapeutics (KROS – Research Report) yesterday and set a price target ...

Oppenheimer lowered the firm’s price target on Keros Therapeutics (KROS) to $23 from $63 and keeps an Outperform rating on the shares after the ...

Scotiabank (TSX:BNS) analysts revised the price target for Keros Therapeutics (NASDAQ:KROS) shares, reducing it to $41 from ...

The company was testing its therapy, cibotercept, in patients with pulmonary arterial hypertension (PAH) - a rare disease ...

OS Therapies OSTX shares rose 57.9% to $6.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $139.5 million. Helius Medical Tech HSDT shares rose 24.29% to $0 ...